Abstract

Acute ischemic stroke (AIS) is a leading cause of disability and mortality worldwide. Recent advancements in neuroprotective therapies have focused on agents that can mitigate ischemic damage and improve neurological recovery. Edaravone, a free radical scavenger, has shown promise as a neuroprotective agent in the treatment of AIS. This review synthesizes available clinical evidence on the efficacy and safety of Edaravone for treating AIS, including its effects on functional recovery, neurological outcomes, and long-term prognosis. The mechanisms of action, pharmacokinetics, and clinical trial results are discussed, highlighting the potential benefits and limitations of Edaravone as a treatment option for AIS. This review also explores the broader implications of Edaravone in stroke management and its place within current therapeutic strategies.